CN107737331A - 一种具有镇静安神作用的复方产品及其制备方法 - Google Patents
一种具有镇静安神作用的复方产品及其制备方法 Download PDFInfo
- Publication number
- CN107737331A CN107737331A CN201711155785.XA CN201711155785A CN107737331A CN 107737331 A CN107737331 A CN 107737331A CN 201711155785 A CN201711155785 A CN 201711155785A CN 107737331 A CN107737331 A CN 107737331A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- compound product
- tranquilizing
- powder
- tranquilizing effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 54
- 230000002936 tranquilizing effect Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000000843 powder Substances 0.000 claims abstract description 40
- 241000209140 Triticum Species 0.000 claims abstract description 36
- 235000021307 Triticum Nutrition 0.000 claims abstract description 36
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 26
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 25
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 25
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 16
- 230000007958 sleep Effects 0.000 claims abstract description 15
- 235000013312 flour Nutrition 0.000 claims abstract description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 14
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 13
- 241000234435 Lilium Species 0.000 claims abstract description 13
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 13
- 229940010454 licorice Drugs 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 8
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 8
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 8
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 8
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 8
- 229960002685 biotin Drugs 0.000 claims abstract description 8
- 235000020958 biotin Nutrition 0.000 claims abstract description 8
- 239000011616 biotin Substances 0.000 claims abstract description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 8
- 229960000304 folic acid Drugs 0.000 claims abstract description 8
- 235000019152 folic acid Nutrition 0.000 claims abstract description 8
- 239000011724 folic acid Substances 0.000 claims abstract description 8
- 229960000367 inositol Drugs 0.000 claims abstract description 8
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 8
- 229960002477 riboflavin Drugs 0.000 claims abstract description 8
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 8
- 239000011719 vitamin A Substances 0.000 claims abstract description 8
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 8
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 8
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 8
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 8
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 8
- 239000011718 vitamin C Substances 0.000 claims abstract description 8
- 229940045997 vitamin a Drugs 0.000 claims abstract description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 7
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 7
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 7
- 239000011570 nicotinamide Substances 0.000 claims abstract description 7
- 229960003080 taurine Drugs 0.000 claims abstract description 7
- 229960003495 thiamine Drugs 0.000 claims abstract description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 7
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 7
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 6
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 3
- -1 bata-carotene Chemical compound 0.000 claims abstract description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000011782 vitamin Substances 0.000 claims abstract description 3
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 3
- 229940046009 vitamin E Drugs 0.000 claims abstract description 3
- 239000011709 vitamin E Substances 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 241000202807 Glycyrrhiza Species 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 8
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 229940051923 vitamin E 15 mg Drugs 0.000 claims description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 238000009461 vacuum packaging Methods 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 1
- 235000019504 cigarettes Nutrition 0.000 claims 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 241000252212 Danio rerio Species 0.000 description 24
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 12
- 206010022437 insomnia Diseases 0.000 description 12
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical class [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种具有镇静安神作用的复方产品,包括以下原料:小麦低聚肽、枣粉、酸枣仁粉、百合粉、甘草粉、γ‑氨基丁酸、复合维生素;复合维生素包括维生素A、维生素D3、维生素E、维生素B1、维生素B2、维生素B12、维生素C、叶酸、生物素、烟酰胺、β‑胡萝卜素、肌醇、牛磺酸。本发明能够非常有效地改善睡眠,其在镇静安神方面具有很大的应用价值。
Description
技术领域
本发明涉及生物技术领域,具体涉及一种具有镇静安神作用的复方产品及其制备方法。
背景技术
小麦低聚肽是从天然小麦蛋白粉经过定向酶切及特定小肽分离技术获得的小分子多肽物质。科学研究发现小麦低聚肽具有多种优异的生物活性,主要有以下功能特点:
(1)有抑制胆固醇上升的作用。小麦低聚肽能促进胰岛素分泌作用,其功能物质是低聚蛋氨酸,可用于调节人的血糖,改善糖尿病症状。小麦肽能阻碍血管紧张素酶的作用,因而有降血压作用。小麦低聚肽的特点之一是含高谷酰胺,能够有效调节神经,也可作肠功能障碍时的特殊营养物质。
(2)具有ACE抑制作用、免疫调节、抗氧化等多种生物活性,能够刺激机体淋巴细胞增殖,增强巨噬细胞吞噬功能,提高机体抵御外界病原体感染的能力,降低机体发病率等。
(3)小麦低聚肽是小麦蛋白酶解产物,能抑制血管紧张素转化酶的活性,使血管紧张素原不能转变成能使血压升高的血管紧张素Ⅱ,从而生理地降低血压,而对正常血压不起用。
(4)抗氧化活性。
小麦低聚肽作为一种应用现代生物工程技术获得的高科技产品,具有多方面的功能应用且安全优势十分明显,但目前其在复方产品中的应用并不多见,没有公开文献表明其作为主要成分用于镇静安神药物。
发明内容
为弥补现有技术的不足,本发明提供一种具有镇静安神作用的复方产品及其制备方法,能够非常有效地改善睡眠,在镇静安神方面具有很大的应用价值。
本发明是通过如下技术方案实现的:
一种具有镇静安神作用的复方产品,其特殊之处在于:包括以下原料:小麦低聚肽、枣粉、酸枣仁粉、百合粉、甘草粉、γ-氨基丁酸、复合维生素;所述复合维生素包括维生素A、维生素D3、维生素E、维生素B1、维生素B2、维生素B12、维生素C、叶酸、生物素、烟酰胺、β-胡萝卜素、肌醇、牛磺酸。
作为优选方案,所述小麦低聚肽中蛋白质量含量大于90%,肽质量含量大于80%。
作为优选方案,所述各原料的质量分数如下:小麦低聚肽35.6%、枣粉30%、酸枣仁粉15%、百合粉17%、甘草粉2%、γ-氨基丁酸0.1%、复合维生素0.3%。
作为优选方案,每100g复方产品中复合维生素的种类和质量如下:维生素A600ug,维生素D3 3ug,维生素E 15mg,维生素B1 400ug,维生素B2 400ug,维生素B12 3ug,维生素C 80mg,叶酸 50ug,生物素30ug,烟酰胺 4.5mg,β-胡萝卜素600ug,肌醇 20mg,牛磺酸 20mg。
本发明的一种具有镇静安神作用的复方产品的制备方法,包括以下步骤:
(1)依次称取小麦低聚肽、枣粉、酸枣仁粉、百合粉、甘草粉、γ-氨基丁酸、复合维生素;
(2)将各原料按照步骤(1)的顺序依次加入混合机内进行充分搅拌;
(3)分装装袋得产品,每包15g。
作为优选方案,步骤(3)中采用真空包装袋进行包装。
本发明的一种具有镇静安神作用的复方产品在镇静安神药物或组合物中的应用。
本发明的一种具有镇静安神作用的复方产品在镇静安神药物或组合物中的应用,所述镇静安神作用表现为改善睡眠。
本发明的有益效果是:本发明基于小麦低聚肽的镇静安神生物活性为基础,通过与山药粉等多种成分形成复方,提供一种小麦低聚肽复方产品,该复方产品能够非常有效地改善睡眠,其在镇静安神方面具有很大的应用价值。
附图说明
附图1是本发明的复方产品对斑马鱼失眠时间的改变情况柱状图,其中,*p <0.05,**p < 0.01,***p < 0.001;
附图2是本发明的复方产品对斑马鱼失眠症的改善作用柱状图,其中,*p < 0.05,**p< 0.01,***p < 0.001。
具体实施方式
下面结合附图和具体实施方式对本发明作进一步详细的说明,以帮助本领域的技术人员对本发明的发明构思、技术方案有更完整、准确和深入的理解,本发明的保护范围包括但不限于以下实施例,在不偏离本申请的精神和范围的前提下任何对本发明的技术方案的细节和形式所做出的修改均落入本发明的保护范围内。
实施例1
本实施例一种具有镇静安神作用的复方产品,包括以下质量分数的原料:小麦低聚肽35.6%、枣粉30%、酸枣仁粉15%、百合粉17%、甘草粉2%、γ-氨基丁酸0.1%、复合维生素0.3%;小麦低聚肽中蛋白质量含量为92%,肽质量含量为81%。
其中,每100g复方产品中复合维生素的种类和质量如下:维生素A 600ug,维生素D3 3ug,维生素E 15mg,维生素B1 400ug,维生素B2 400ug,维生素B12 3ug,维生素C 80mg,叶酸 50ug,生物素30ug,烟酰胺 4.5mg,β-胡萝卜素600ug,肌醇 20mg,牛磺酸 20mg。
本实施例的一种具有镇静安神作用的复方产品的制备方法,包括以下步骤:
(1)依次称取小麦低聚肽、枣粉、酸枣仁粉、百合粉、甘草粉、γ-氨基丁酸、复合维生素;
(2)将各原料按照步骤(1)的顺序依次加入混合机内进行充分搅拌;
(3)采用真空袋分装装袋得产品,每包15g;该复方产品能够非常有效地改善睡眠,在睡眠不佳的人群中具有极大的应用价值。
实施例2
本实施例一种具有镇静安神作用的复方产品,包括以下质量分数的原料:小麦低聚肽34.6%、枣粉31%、酸枣仁粉16%、百合粉16%、甘草粉2%、γ-氨基丁酸0.1%、复合维生素0.3%;小麦低聚肽中蛋白质量含量为92%,肽质量含量为81%。
其中,每100g复方产品中复合维生素的种类和质量如下:维生素A 600ug,维生素D3 3ug,维生素E 15mg,维生素B1 400ug,维生素B2 400ug,维生素B12 3ug,维生素C 80mg,叶酸 50ug,生物素30ug,烟酰胺 4.5mg,β-胡萝卜素600ug,肌醇 20mg,牛磺酸 20mg。
本实施例的一种具有镇静安神作用的复方产品的制备方法,包括以下步骤:
(1)依次称取小麦低聚肽、枣粉、酸枣仁粉、百合粉、甘草粉、γ-氨基丁酸、复合维生素;
(2)将各原料按照步骤(1)的顺序依次加入混合机内进行充分搅拌;
(3)采用真空袋分装装袋得产品,每包15g;该复方产品能够非常有效地改善睡眠,在睡眠不佳的人群中具有极大的应用价值。
实施例3
本实施例一种具有镇静安神作用的复方产品,包括以下质量分数的原料:小麦低聚肽36.6%、枣粉31%、酸枣仁粉14%、百合粉16%、甘草粉2%、γ-氨基丁酸0.1%、复合维生素0.3%;小麦低聚肽中蛋白质量含量为92%,肽质量含量为81%。
其中,每100g复方产品中复合维生素的种类和质量如下:维生素A 600ug,维生素D3 3ug,维生素E 15mg,维生素B1 400ug,维生素B2 400ug,维生素B12 3ug,维生素C 80mg,叶酸 50ug,生物素30ug,烟酰胺 4.5mg,β-胡萝卜素600ug,肌醇 20mg,牛磺酸 20mg。
本实施例的一种具有镇静安神作用的复方产品的制备方法,包括以下步骤:
(1)依次称取小麦低聚肽、枣粉、酸枣仁粉、百合粉、甘草粉、γ-氨基丁酸、复合维生素;
(2)将各原料按照步骤(1)的顺序依次加入混合机内进行充分搅拌;
(3)采用真空袋分装装袋得产品,每包15g;该复方产品能够非常有效地改善睡眠,在睡眠不佳的人群中具有极大的应用价值。
实施例4
动物实验评价
1. 浓度组别
实验1组 正常对照组(不做任何处理)
实验2组 模型对照组
实验3组 阳性对照药氯化锂 500 μM
实验4组 小麦肽纯肽纯肽 1012 µg/mL
实验5组 实施例1所得产品(以下简称复方产品) 222 µg/mL
实验6组 复方产品 666 µg/mL
实验7组 复方产品 2000 µg/mL
2. 模型制作
用咖啡因处理野生型AB系斑马鱼24 h,建立斑马鱼失眠模型。
3. 浓度确定依据
依据浓度摸索实验结果,“复方产品在浓度为2000 µg/mL时斑马鱼无不良反应情况出现,因此复方产品最大给药浓度为2000 µg/mL,药效学评价浓度设置为222、666和2000 µg/mL浓度。
4. 实验方法
4.1 最大耐受浓度(MTC)摸索
随机选取5 dpf野生型AB系斑马鱼于6孔板中,每孔30尾。用咖啡因诱导斑马鱼建立失眠模型,分别水溶给予肽类复方产品1、10、50、100、250、500、1000和2000 μg/mL浓度,同时设置正常对照组和模型对照组,复方产品与诱导剂共同处理结束后,观察斑马鱼反应情况,确定复方产品对斑马鱼的最大耐受浓度(MTC)。
4.2 镇静安神作用评价
随机选取5 dpf野生型AB系斑马鱼于6孔板中,每孔30尾。用咖啡因诱导斑马鱼建立失眠模型,分别水溶给予肽类复方产品222、666和2000 µg/mL浓度,小麦肽纯肽1012 µg/mL浓度,阳性对照药氯化锂500 μM浓度,同时设置正常对照组和模型对照组。复方产品与诱导剂共同处理结束后,每个实验组随机选择10尾斑马鱼,应用行为分析仪测定斑马鱼处于失眠状态的时间(T),失眠状态的时间进行统计分析,以统计学意义评价复方产品对斑马鱼的镇静安神作用。复方产品对失眠症斑马鱼睡眠改善的计算公式如下:
统计学分析采用方差分析和Dunnett’s T-检验,p < 0.05表明具有显著性差异。
实验结果
5.1 MTC
结果显示:“复方产品在浓度为2000 µg/mL时对咖啡因诱导失眠的模型斑马鱼无不良反应情况出现,因此复方产品对咖啡因诱导失眠的模型斑马鱼最大给药浓度为2000 µg/mL,药效学评价浓度设置为222、666和2000 µg/mL浓度,详见下表:
最大耐受浓度摸索情况
5.2 镇静安神作用评价
结果显示:模型对照组斑马鱼失眠时间(6733秒)与正常对照组失眠时间(5417秒)比较p < 0.001,表明模型建立成功;阳性对照药氯化锂斑马鱼失眠时间(5540秒)与模型对照组比较p < 0.01,睡眠改善作用为91%,表明氯化锂对斑马鱼失眠症具有明显的改善作用;小麦肽纯肽1012 µg/mL浓度斑马鱼失眠时间(5974秒)与模型对照组比较p < 0.05,睡眠改善作用为58%,表明小麦肽复方产品供试品对照纯肽对斑马鱼失眠症具有明显的改善作用;小麦肽复方产品222、666和2000 µg/mL浓度斑马鱼失眠时间分别为5961、5636、5468秒,与模型对照组比较p < 0.01 & p < 0.001,睡眠改善作用分别为59%、83%和96%。提示小麦肽复方产品在本实验浓度条件下具有明显的镇静安神作用。详见下表以及附图1、2:
小麦肽复方产品对斑马鱼失眠症的改善作用定量数据(n=14)
与模型对照组比较,*p < 0.05,**p < 0.01,***p < 0.001。
Claims (8)
1.一种具有镇静安神作用的复方产品,其特征在于:包括以下原料:小麦低聚肽、枣粉、酸枣仁粉、百合粉、甘草粉、γ-氨基丁酸、复合维生素;所述复合维生素包括维生素A、维生素D3、维生素E、维生素B1、维生素B2、维生素B12、维生素C、叶酸、生物素、烟酰胺、β-胡萝卜素、肌醇、牛磺酸。
2.根据权利要求1所述的一种具有镇静安神作用的复方产品,其特征在于:所述小麦低聚肽中蛋白质量含量大于90%,肽质量含量大于80%。
3.根据权利要求1所述的一种具有镇静安神作用的复方产品,其特征在于:所述各原料的质量分数如下:小麦低聚肽35.6%、枣粉30%、酸枣仁粉15%、百合粉17%、甘草粉2%、γ-氨基丁酸0.1%、复合维生素0.3%。
4.根据权利要求3所述的一种具有镇静安神作用的复方产品,其特征在于:每100g复方产品中复合维生素的种类和质量如下:维生素A 600ug,维生素D3 3ug,维生素E 15mg,维生素B1 400ug,维生素B2 400ug,维生素B12 3ug,维生素C 80mg,叶酸 50ug,生物素30ug,烟酰胺 4.5mg,β-胡萝卜素600ug,肌醇 20mg,牛磺酸 20mg。
5.根据权利要求1-4中任一项所述的一种具有镇静安神作用的复方产品的制备方法,其特征在于:包括以下步骤:
(1)依次称取小麦低聚肽、枣粉、酸枣仁粉、百合粉、甘草粉、γ-氨基丁酸、复合维生素;
(2)将各原料按照步骤(1)的顺序依次加入混合机内进行充分搅拌;
(3)分装装袋得产品,每包15g。
6.根据权利要求5所述的一种具有镇静安神作用的复方产品的制备方法,其特征在于:步骤(3)中采用真空包装袋进行包装。
7.根据权利要求1所述的一种具有镇静安神作用的复方产品在镇静安神药物或组合物中的应用。
8.根据权利要求7所述的一种具有镇静安神作用的复方产品在镇静安神药物或组合物中的应用,其特征在于:所述镇静安神作用表现为改善睡眠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711155785.XA CN107737331A (zh) | 2017-11-20 | 2017-11-20 | 一种具有镇静安神作用的复方产品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711155785.XA CN107737331A (zh) | 2017-11-20 | 2017-11-20 | 一种具有镇静安神作用的复方产品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107737331A true CN107737331A (zh) | 2018-02-27 |
Family
ID=61238500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711155785.XA Pending CN107737331A (zh) | 2017-11-20 | 2017-11-20 | 一种具有镇静安神作用的复方产品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107737331A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109198353A (zh) * | 2018-09-25 | 2019-01-15 | 西安源森生物科技有限公司 | 一种镇痛安神固体饮料及其制备方法 |
CN110179125A (zh) * | 2019-05-29 | 2019-08-30 | 山东腾贵医药有限公司 | 一种促进产后恢复的组合物及其制备方法 |
CN111603550A (zh) * | 2020-06-29 | 2020-09-01 | 中食都庆(山东)生物技术有限公司 | 一种含小麦低聚肽的组合物及其应用 |
CN111990296A (zh) * | 2020-08-06 | 2020-11-27 | 南京新环检测科技有限公司 | 一种适用于评价多种保健食品改善睡眠功效的方法 |
CN113476551A (zh) * | 2021-07-13 | 2021-10-08 | 上海阶平医院管理有限公司 | 一种治疗失眠的磁疗液及其磁疗器 |
CN116210896A (zh) * | 2022-12-12 | 2023-06-06 | 福州三合元生物科技有限公司 | 一种具有伽马氨基丁酸的保健品制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110709A (zh) * | 2011-11-16 | 2013-05-22 | 北京康比特体育科技股份有限公司 | 一种改善睡眠的组合物及其制备方法 |
CN104855956A (zh) * | 2015-04-13 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 失眠医学配方食品 |
CN104856000A (zh) * | 2015-04-23 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 失眠非全营养配方食品 |
CN106492048A (zh) * | 2017-01-03 | 2017-03-15 | 乐康珍品(北京)健康科技有限公司 | 一种促睡眠制剂及其制备方法 |
CN106690309A (zh) * | 2016-12-27 | 2017-05-24 | 天津市康世生物技术有限公司 | 一种具有缓解焦虑、改善睡眠作用的组合物及其应用 |
-
2017
- 2017-11-20 CN CN201711155785.XA patent/CN107737331A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110709A (zh) * | 2011-11-16 | 2013-05-22 | 北京康比特体育科技股份有限公司 | 一种改善睡眠的组合物及其制备方法 |
CN104855956A (zh) * | 2015-04-13 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 失眠医学配方食品 |
CN104856000A (zh) * | 2015-04-23 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 失眠非全营养配方食品 |
CN106690309A (zh) * | 2016-12-27 | 2017-05-24 | 天津市康世生物技术有限公司 | 一种具有缓解焦虑、改善睡眠作用的组合物及其应用 |
CN106492048A (zh) * | 2017-01-03 | 2017-03-15 | 乐康珍品(北京)健康科技有限公司 | 一种促睡眠制剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
傅文录: "《失眠防治300问》", 31 January 2005, 中国中医药出版社 * |
萨英: "《舌尖上的革命》", 31 December 2013, 贵州科技出版社 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109198353A (zh) * | 2018-09-25 | 2019-01-15 | 西安源森生物科技有限公司 | 一种镇痛安神固体饮料及其制备方法 |
CN110179125A (zh) * | 2019-05-29 | 2019-08-30 | 山东腾贵医药有限公司 | 一种促进产后恢复的组合物及其制备方法 |
CN111603550A (zh) * | 2020-06-29 | 2020-09-01 | 中食都庆(山东)生物技术有限公司 | 一种含小麦低聚肽的组合物及其应用 |
CN111990296A (zh) * | 2020-08-06 | 2020-11-27 | 南京新环检测科技有限公司 | 一种适用于评价多种保健食品改善睡眠功效的方法 |
CN111990296B (zh) * | 2020-08-06 | 2022-05-10 | 南京新环检测科技有限公司 | 一种适用于评价多种保健食品改善睡眠功效的方法 |
CN113476551A (zh) * | 2021-07-13 | 2021-10-08 | 上海阶平医院管理有限公司 | 一种治疗失眠的磁疗液及其磁疗器 |
CN116210896A (zh) * | 2022-12-12 | 2023-06-06 | 福州三合元生物科技有限公司 | 一种具有伽马氨基丁酸的保健品制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107737331A (zh) | 一种具有镇静安神作用的复方产品及其制备方法 | |
JP2021521244A (ja) | 女性の生殖能力の改善のための異なる薬物動態プロファイルを有するレスベラトロルの混合物に基づく製剤の使用 | |
JP2011178794A (ja) | 高血糖症の治療もしくは予防、または血糖の安定化に用いられる酵母細胞壁 | |
KR100414140B1 (ko) | 건강조성물 | |
CN108714208A (zh) | 组合物、其制备方法、应用和缓解压力、改善睡眠的产品 | |
JPH04327537A (ja) | 組織における充分な細胞内グルタチオンを保証する方法 | |
HUP0400662A2 (hu) | A hosszú PTX3-pentraxin és a női termékenység | |
KR20210002461A (ko) | 녹농균 감염증의 예방 및/또는 치료제 | |
CN105497059B (zh) | 一种石斛提取物与铁的复合物及其制备方法与应用 | |
CN107028101A (zh) | 一种补肾益精的组合物及其制备方法 | |
CN111759880A (zh) | 淫羊藿药材提取物及其在预防或治疗冠状病毒中的应用 | |
KR20090034302A (ko) | 수면 유도용 경구제, 스트레스성 불면증 개선용 경구제 | |
US20220218772A1 (en) | Mushroom blend for increasing butyrate production in the gut biome | |
CN114272270A (zh) | 格氏乳杆菌lg08在制备防治痛风相关疾病的产品中的用途 | |
CN106999514A (zh) | 含有亚铁氨基酸螯合物的组合物在制备改善糖尿病的药物中的用途 | |
CN105963330B (zh) | 神秘果制剂及其应用 | |
CN106620012A (zh) | 青梅酵素营养液及其制备方法 | |
CN107510701B (zh) | 一种儿童补铁与维生素的组合物及其制备方法和应用 | |
CN103860543B (zh) | 异佛司可林在防治慢性阻塞性肺病中的应用 | |
CN107890563A (zh) | 一种具有抗结肠炎功能的复方产品及其制备方法 | |
WO2016086776A1 (zh) | 一种包含绿原酸的抗真菌复方制剂及其应用 | |
Soni et al. | Simultaneous determination of vitamins B1, B2 and B6 in multivitamin tablet and biological fluid by RP-HPLC | |
CN106222223B (zh) | 人血白蛋白的生产方法 | |
CN107753928A (zh) | 一种具有增加骨密度功能的复方产品及其制备方法 | |
RU2182806C2 (ru) | Пищевая биологически активная добавка |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180227 |